

Interview Summary	Application No. 09/841,426	Applicant(s) NYCE, JONATHAN W.	
	Examiner Shaojia A Jiang	Art Unit 1617	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Shaojia A Jiang. (3) ____.
- (2) Mr. Albert Halluin. (4) ____.

Date of Interview: 17 November 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: ____.

Claim(s) discussed: all claims.

Identification of prior art discussed: cited prior art.


Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The examiner discussed the priority and pointed out that the instant application is a CIP and that the parent applications 08/861962 now patent 6,087,351, and 08/393863 now patent 5,660,835 upon which priority is claimed, fails to provide adequate support under 35 U.S.C. 112 for a single pharmaceutical composition comprising the combination of DHEA and ubiquinone as claimed herein because, for example, the parent case, 5,660,835 is drawn to a method of treatment therein comprising DHEA alone, and but merely mentions "ubiquinone may be administered concurrently with DHEA" simultaneously or at different time (see 5,660,835 col.6 line 45-53) and also teaches away from the instant claims, i.e., by teaching "where the ubiquinone is formulated ... separately from DHEA" (see 5,660,835 col.7 lines 16-17)..